Clinical trial
A Phase 2b Single Arm, Repeat Dose Study to Evaluate the Pharmacokinetic Profile, Safety, and Tolerability of A New Formulation of Cabotegravir LA Injected Intramuscularly Q4M in Adolescent and Adult Participants at Risk of HIV Acquisition
NCT06741397 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b Single Arm, Repeat Dose Study to Evaluate the Pharmacokinetic Profile, Safety, and Tolerability of A New Formulation of Cabotegravir LA Injected Intramuscularly Q4M in Adolescent and Adult Participants at Risk of HIV Acquisition
- Lead sponsor
- ViiV Healthcare
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- December 20, 2024
- Completion date
- August 30, 2029
- Enrollment
- 229 (actual)
- Sites
- 27
Conditions
As the registry lists them; a condition with its own page is linked.